These data support the international implementation of the recent ATS/JRS LAM Clinical Practice Guidelines recommendation for using VEGF-D when diagnosing LAM [15, 16] and as an eligibility criterion in clinical trials, including international multicenter trials [8, 19]. Here, VEGFD is linked to lymphangioleiomyomatosis.